QuidelOrtho Corporation Common Stock (QDEL) is a publicly traded Healthcare sector company. As of May 21, 2026, QDEL trades at $11.95 with a market cap of $739.19M and a P/E ratio of -0.67. QDEL moved +4.48% today. Year to date, QDEL is -60.38%; over the trailing twelve months it is -63.22%. Its 52-week range spans $9.92 to $49.45. Analyst consensus is neutral with an average price target of $12.03. Rallies surfaces QDEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
QuidelOrtho Q1 revenue $620M, POC sales down 34% as guidance trimmed: QuidelOrtho reported Q1 revenue of $620 million, driven by a 34% decline in point-of-care sales and an 8% rise in immunohematology revenue. The company posted a GAAP net loss of $92 million, adjusted EBITDA of $109 and cut full-year revenue outlook to $2.70–2.75 billion with $615–630 million in adjusted EBITDA.
| Metric | Value |
|---|---|
| Price | $11.95 |
| Market Cap | $739.19M |
| P/E Ratio | -0.67 |
| EPS | $-17.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $49.45 |
| 52-Week Low | $9.92 |
| Volume | 316 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.66B |
| Net Income | $-1.21B |
| Gross Margin | 0.00% |
6 analysts cover QDEL: 0 strong buy, 1 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $12.03.